Stock Market Reviews

IRD (Opus Genetics, Inc.) News

Get the latest news, insights, and market updates on IRD (Opus Genetics, Inc.). Explore the news page 3 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Opus Genetics to Participate in Chardan's 9th Annual Genetic Medicines Conference
  RESEARCH TRIANGLE PARK, N.C., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (the “Company” or “Opus Genetics”), a clinical-stage biopharmaceutical company developing gene therapies for the treatment of inherited retinal diseases (IRDs) and small molecule therapies for other ophthalmic disorders, announced today that Ash Jayagopal, PhD, MBA, Chief Scientific and Development Officer, will present a corporate update at Chardan's 9th Annual Genetic Medicines Conference on Tuesd
  Oct 14, 2025 - $IRD
• Opus Genetics to Present at Upcoming Medical and Industry Conferences in October 2025
  RESEARCH TRIANGLE PARK, N.C., Oct. 02, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage biopharmaceutical company developing gene therapies for the treatment of inherited retinal diseases (IRDs) and small molecule therapies for other ophthalmic disorders, today announced that it will present the positive clinical results from both its IRD gene therapy and Phentolamine Ophthalmic Solution 0.75% (POS) programs at the following medical and industry conferences in October
  Oct 2, 2025 - $IRD
• Are You Looking for a Top Momentum Pick? Why Opus Genetics, Inc. (IRD) is a Great Choice
  Does Opus Genetics, Inc. (IRD) have what it takes to be a top stock pick for momentum investors? Let's find out.
  Oct 1, 2025 - $IRD
• Opus Genetics Reports Positive Pediatric Data from OPGx-LCA5 Phase 1/2 Trial in Leber Congenital Amaurosis Type 5 (LCA5)
  Pediatric participants demonstrated large gains in cone-mediated vision; therapy remains well tolerated with no ocular serious adverse events or dose-limiting toxicitiesLasting, durable responses observed out to 18 months in adult participantsExpected FDA Meeting in Q4 2025Management to Host Webcast and Conference Call Today at 8:30 A.M. ET RESEARCH TRIANGLE PARK, N.C., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage biopharmaceutical company developing gen
  Sep 30, 2025 - $IRD
• Institutions profited after Opus Genetics, Inc.'s (NASDAQ:IRD) market cap rose US$15m last week but private equity firms profited the most
  Key Insights Significant control over Opus Genetics by private equity firms implies that the general public has more...
  Sep 26, 2025 - $IRD
• Zacks.com featured highlights include Sally Beauty, Broadstone Net Lease and Opus Genetics
  Sally Beauty, Broadstone Net Lease, and Opus Genetics make Zacks' "Under $20 Breakout Trio" list for investors eyeing growth.
  Sep 16, 2025 - $IRD
• The Under $20 Breakout Trio Investors Shouldn't Ignore
  Sally Beauty, Broadstone Net Lease and Opus Genetics emerge as today's breakout stock picks under $20, flagged for potential near-term gains.
  Sep 15, 2025 - $IRD